REFRACTORY PLASMA CELL MYELOMA

This study is testing a two-part drug combination to control multiple myeloma, a blood cancer, in patients whose disease has come back or stopped responding to prior treatments. It combines an immunotherapy drug that helps the immune system attack cancer with other drugs that blo…

This study is testing whether the immunotherapy drug nivolumab can help control blood cancers that have returned, stopped responding, or are still detectable after a patient has already received CAR-T cell therapy. It is for adults with specific types of lymphoma, leukemia, or mu…

This early-stage trial is testing whether a patient's own immune cells can be grown in a lab to fight multiple myeloma that has returned or stopped responding to other treatments. Doctors take T-cells from the patient's blood, grow them to target a specific protein found on cance…

This early-stage trial is testing the safety of combining two drugs—venetoclax and tocilizumab—for multiple myeloma that has returned or stopped responding to treatment. The study focuses on patients whose cancer has a specific genetic change called t(11;14). Researchers want to …

This early-phase trial is testing the safety and best dose of a two-drug combination (selinexor and choline salicylate) for adults with advanced blood cancers that have returned or stopped responding to standard treatments. The study includes patients with non-Hodgkin lymphoma, H…

This study is testing whether adding a modified virus (pelareorep) to a combination of standard chemotherapy and immunotherapy drugs is safe and more effective for people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if the virus …

This study is testing a combination of three drugs—isatuximab, carfilzomib, and pomalidomide—for adults with multiple myeloma that has come back (relapsed) or stopped responding to treatment (refractory). The goal is to see if this combination can control the cancer and for how l…